Literature DB >> 30784073

Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing.

Pierre Cappy1, Valérie Barlet2, Quentin Lucas1, Xavier Tinard3, Josiane Pillonel4, Sylvie Gross5, Pierre Tiberghien5,6, Syria Laperche1.   

Abstract

BACKGROUND: In France, the risk of HIV transmission by transfusion was reduced by implementing pooled nucleic acid testing (NAT) in 2001 and individual NAT in 2010. We report here the first case in France of transfusion of human immunodeficiency virus (HIV)-infected blood donated during HIV pre-ramp-up phase that tested individual NAT negative.
METHODS: Blood donations are screened for HIV antibodies and HIV RNA (ProcleixUltrio, Grifols; limit of detection at 95%, 23 copies/mL). When a repeat donor tests positive for HIV, a repository sample from the previous donation is tested with the Cobas Taqman HIV-1 test (CTM, Roche; limit of detection at 95%, 17 copies/mL).
RESULTS: In August 2017, a 57-year-old male repeat donor was screened positive for HIV antibodies and RNA (plasma viral load, 11,599 copies/mL). The previous donation had tested negative with Ultrio in March 2017 but was positive with an unquantifiable plasma viral load when tested with CTM. Sequencing showed no mismatch between Ultrio primers/probes and the target sequence. HIV transmission was excluded by lookback studies in the recipient of platelets, which had been pathogen reduced, but not in the recipient of RBCs due to premature death.
CONCLUSION: This case demonstrates that the risk of contaminated donations due to the early HIV infection phase going undetected by highly sensitive NAT is real but exceptional. The absence of transmission to the platelets recipient could be due to the very low viral inoculum and/or to the efficacy of the viral inactivation. This case also highlights the additional value of a systematic donation archiving and the importance of donor education and predonation selection.
© 2019 AABB.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30784073     DOI: 10.1111/trf.15203

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates.

Authors:  A M Hashem; A M Hassan; A M Tolah; M A Alsaadi; Q Abunada; G A Damanhouri; S A El-Kafrawy; M Picard-Maureau; E I Azhar; S I Hindawi
Journal:  Transfus Med       Date:  2019-11-06       Impact factor: 2.019

3.  Deep sequencing applied to the analysis of viromes in patients with beta-thalassemia.

Authors:  Ian Nunes Valença; Rafael Bezerra Dos Santos; Kamila Chagas Peronni; Virginie Sauvage; Mathias Vandenbogaert; Valérie Caro; Wilson Araújo da Silva Junior; Dimas Tadeu Covas; Ana Cristina Silva-Pinto; Syria Laperche; Simone Kashima; Svetoslav Nanev Slavov
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-05-24       Impact factor: 1.846

4.  Personal Freedom and Public Responsibility: Remaining Questions after First Case of HIV Transmission via Blood Transfusion in North Serbia.

Authors:  Jasmina Grujić; Nevenka Bujandrić; Pavle Banović
Journal:  Healthcare (Basel)       Date:  2022-07-27

5.  Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.

Authors:  Jose A Cancelas; Jamie R Genthe; Moritz Stolla; Neeta Rugg; S Lawrence Bailey; Shawnagay Nestheide; Beth Shaz; Samantha Mack; Kadi Schroeder; Waseem Anani; Zbigniew M Szczepiorkowski; Larry J Dumont; Subramanian Yegneswaran; Laurence Corash; Nina Mufti; Richard J Benjamin; Anna C Erickson
Journal:  Transfusion       Date:  2022-07-09       Impact factor: 3.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.